tbuckley/cabot-search huggingface dataset:
AB0734 Evaluation of cardiovascular risk profiles in a population of patients with ankylosing spondylitis: a cross-sectional study
Authors: A Ghrbel, M Turki, A Feki, B Belhasan, R Akrout, M Chtourou, M Neifar, H Fourati, S Baklouti, F Ayedi
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> ankylosing spondylitis (AS), like the other chronic inflammatory rheumatic diseases, is considered to have higher cardiovascular (CV) risk (1). The Etiopathogenesis is not clearly defined. <h3>Objectives</h3> assess the early biological markers of atherosclerosis in Tunisian patients with AS compared with healthy controls and evaluate the relationship between Systematic Coronary Risk Evaluation (SCORE) for CV-related mortality and biological markers (2). <h3>Methods</h3> This was a cross-sectional study conducted since June 2015 until October 2016 including patients with AS in the South of Tunisia and matched controls with sex, age, body mass index (BMI) and smoking. Patients diagnosed with AS should fulfill the modified New York criteria. For patients and controls, we measured total cholesterol (TC), high density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein (Apo) AI, ApoB, lipoprotein (a) [Lp(a)] and C-Reactive Protein (CRP). Low-density lipoprotein (LDL) cholesterol was calculated with the Friedewald formula. SCORE was calculated through the use of sex, age, systolic pressure, smoking and TC. Comparisons were performed using two sample t-tests for parametric values and Wilcoxon Mann-Whitney Test for non-parametric values. Correlation analyses were performed with Spearman rank. <h3>Results</h3> Overall 79 patients with AS and 79 controls were included. The mean age was (43.81±14.29 vs 44,27±14 years). The sex ratio (M/F) was 2/1 and the mean BMI was (25.9±5.3 vs 25.76±3.5 kg/m<sup>2</sup>). AS patients had significantly lower levels of HDL and TC and a higher level of CRP and atherogenic index (TC/HDL, ApoB/ApoA). AS patients had higher CV mortality than controls (1.1±1.8 vs 0,51±1.13%, p=0.01). The frequency of high cardiovascular risk was higher in AS patients (5 vs 2, p=0.4). The correlation between SCORE9s risk and biological markers were positive with TC, LDL, Lp (a), TC/HDL ratio and LDL/HDL ratio. <h3>Conclusions</h3> AS patients are at a greater cardiovascular risk due to a higher CRP rate, atherogenic index and 10-year risk SCOREs of CV mortality. So, the dyslipidaemia and inflammation could be the aetiology of cardiovascular risk. <h3>References</h3> Mathieu S, Soubrier M. Le risque cardiovasculaire dans la spondyloarthrite axiale. Presse Med. 2015;44(9):907–11. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987–1003. <h3>Disclosure of Interest</h3> None declared
SAT0158 Efficacy of switching from etanercept to adalimumab in rheumatoid arthritis and psoriatic arthritis patients who experienced a first-line biologic therapy failure: the fearless study
Authors: EG Favalli, A Becciolini, A Carletto, F Conti, G Amato, E Fusaro, L Quartuccio, A Lo Monaco, M Benucci, F Salaffi, A Semeraro, M Biggioggero, S Parisi, F Ceccarelli, I Piazza, R Foti
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The strategy for the choice of the second biologic agent after the failure of the first TNF inhibitor (TNFi) is still an unclear aspect in the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Switching between structurally different TNFis (from etanercept [ETN] to monoclonal antibody [mAb] or vice versa) has been proposed as a more effective procedure than switching among different mAbs, but to date no study has been specifically focused on exploring this topic. <h3>Objectives</h3> To evaluate the comparative 2-year retention rate and the 12-month efficacy of adalimumab (ADA) as second biologic agent in etanercept (ETN) non-responder RA and PsA patients in a multicentre retrospective study. <h3>Methods</h3> All RA and PsA patients from 11 Italian Rheumatology Units treated with ADA after a first-course ETN failure and with at least 12-month follow-up were retrospectively collected in a multicentre registry. Data analysis was limited to the period from January 2002 to May 2016. Two-year ADA retention rate was calculated by Kaplan-Meier method. 12-month ADA response was defined as achievement of disease activity score 28 calculated by using erythrosedimentation (DAS28-ESR) &lt;2.6 (remission) or &gt;2.6 and &lt;3.2 (low disease activity, LDA). Sub-analyses according to reason for ETN discontinuation and concomitant methotrexate in RA and PsA patients have been performed. <h3>Results</h3> The study population (219 patients) included 117 RA (female 85.5%, mean [± standard deviation, SD] age 53.2±13.5 years, mean [±SD] disease duration 10.1±7.7; positive rheumatoid factor 70.2%; positive anti-citrullinated peptide antibodies [ACPA] 59.6%; mean [±SD] baseline DAS28-ESR 4.97±1.3; MTX users 64.9%) and 102 PsA (female 63.7%; mean [±SD] age 51.7±10.6; mean [±SD] disease duration 7.1±5.1; mean [±SD] baseline DAS28-ESR 4.4±1.1; MTX users 50%). The 2-year retention rate was 48.2% in RA and 56.5% in PsA patients, irrespective of reason for ETN discontinuation. Similarly, concomitant MTX was not associated with an increased drug survival in both RA (p=0.09) and PsA (p=0.969) subgroup. 12-month clinical remission and LDA were achieved respectively in 27.3% and 23.9% RA patients, and 27.4% and 23.5% PsA patients. <h3>Conclusions</h3> In our large real-life cohort, the use of ADA in primary and secondary ETN failures was highly effective in both RA and PsA patients, with more than 50% of ADA treated patients achieving remission or LDA. Reasons for ETN discontinuation were not associated with different ADA clinical response, as well as concomitant MTX. <h3>Disclosure of Interest</h3> None declared
AB0204 Disease factors associated to abnormal intima-media thickness in mexican mestizo rheumatoid arthritis patients
Authors: DA Galarza-Delgado, JR Azpiri-Lopez, IJ Colunga-Pedraza, RE Ramos-Cazares, FJ Torres-Quintanilla, A Valdovinos-Bañuelos, RI Arvizu-Rivera, A Martinez-Moreno, JA Cardenas-de la Garza, R Vera-Pineda, G Elizondo-Riojas, JI Garcia-Colunga
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Atherosclerotic cardiovascular disease (ASCVD) is the main mortality cause in patients with rheumatoid arthritis (RA) (1). It has been proven that the carotid intima-media thickness (CIMT) measured with carotid duplex ultrasonography (US) is an important ASCVD predictor with a measurement ≥0.9 mm (2–4). <h3>Objectives</h3> To characterize the disease factors related with abnormal carotid duplex US findings in Mexican mestizo patients with RA. <h3>Methods</h3> In a cross-sectional setting, we enrolled consecutive RA patients. Patients with overlap syndromes, personal history of ASCVD, dyslipidemia and previous use of any statin were excluded. A board-certified radiologist performed a bilateral carotid duplex US to all patients. Abnormal CIMT was defined as ≥0.9 mm (hypertrophy ≥0.9 – 1.2 mm and carotid plaque ≥1.2 mm). A clinical history and blood tests were performed at the time of the patient9s visit. Disease activity was measured with Disease Activity Score using 28 joints–C-reactive protein (DAS28-CRP). <h3>Results</h3> We enrolled 57 patients. Demographic characteristics are shown in table 1. A total of 30 (52.2%) patients had an abnormal CIMT. US findings are shown in table 2. A significant correlation between abnormal CIMT and RA disease duration (p=0.04), as well as between the former and anti-cyclic citrullinated peptide antibodies (ACPA) positivity (p=0.033) was found. <h3>Conclusions</h3> There is a strong relationship between CIMT and the chronic inflammatory process of RA, as well as ACPA positivity. These results might be influenced by the high mean disease duration of our patients. Prospective studies that evaluate CIMT among disease duration intervals are necessary to support these findings. <h3>References</h3> Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–9. Galarza-Delgado DA, Esquivel-Valerio JA, Garza-Elizondo MA, Gongora-Rivera F, Munoz-De Hoyos JL, Serna-Pena G. Carotid atherosclerosis in patients with rheumatoid arthritis and rheumatoid nodules. Reumatol Clin. 2013;9(3):136–41. Mateo I, Morillas P, Quiles J, Castillo J, Andrade H, Roldan J, et al. What measure of carotid wall thickening is the best atherosclerotic loading score in the hypertensive patient: maximum or mean value? Rev Esp Cardiol. 2011;64(5):417–20. <h3>Disclosure of Interest</h3> None declared
Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
Authors: Aayoung Hong, Gatien Moriceau, Lu Sun, Shirley Lomeli, Marco Piva, Robert Damoiseaux, Sheri L. Holmen, Norman E. Sharpless, Willy Hugo, Roger S. Lo
Journal: Cancer Discovery (2017)

Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fitness upon experimental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after a drug holiday. Here, we uncovered and therapeutically exploited the mechanisms of MAPKi addiction in MAPKi-resistant
Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies
Authors: Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps, Dennis Benjamin
Journal: Blood (2017)
AB0332 Does a community interface rheumatoid arthritis annual review improve patient care?
Authors: J Mcdonald, R Haigh, D Murphy
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patients with rheumatoid arthritis are known to have a long term disability and increased risk of extra-articular comorbidities. EULAR guidelines suggest annual review of cardiovascular risk in patients with rheumatoid arthritis [1] whilst UK national (NICE) guidelines suggest a more holistic annual review to look at the impact of the disease on quality of life as well as co-morbidities [2]. <h3>Objectives</h3> Our aim was to look at the annual reviews currently taking place in primary care to see how frequently patient co-morbidities were assessed and documented. We then implemented a formal community rheumatology interface review to assess whether this improved patient care. <h3>Methods</h3> A large primary care practice (16,000 patients) was offered a community rheumatology interface review by a secondary care clinician. A search was undertaken for patients with rheumatoid arthritis who had attended for an annual primary care review between December 2015–2016. Of these 30 reviews were selected and we assessed how frequently the following were recorded; DAS28, HAQ score, FRAX score, Q-Risk2 (CV risk assessment tool) and screening for depression. Once we had analysed these results we implemented a community rheumatology interface review and assessed compliance with the above outcomes had improved compared to standard primary care management. <h3>Results</h3> In patients assessed prior to implementation of interface review, we found that a DAS28 score was recorded in 0%, HAQ score in 0%, FRAX in 13%, Q-Risk2 in 10% and depression screening in 23%. In comparison, patients assessed by a community rheumatology interface clinician recorded DAS28 in 100%, HAQ score in 100%, FRAX in 100%, Q-Risk2 in 100% and depression screening was recorded in 100%. Based on improved interface review 7 patients (23%) were sent for DEXA scanning or started on a bisphosphonate, we discussed cardiovascular risk and starting a statin in 8 patients (26%) and 7 patients (23%) required follow-up for mental health. Of the 30 patients in this cohort all patients reported full adherence to their anti-rheumatic regime. <h3>Conclusions</h3> 1. An annual review with a rheumatology interface practitioner is of benefit in holistic patient care and improved compliance with all domains of the annual review. 2. Management of metabolic bone, cardiovascular and mental health issues was improved, according to current national guidelines. <h3>References</h3> Peters M et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010 69:325–331. National Institute for Health and Clinical Excellence (NICE) (2009). Rheumatoid Arthritis in Adults: Management. Clinical Guideline 79. London: NICE. <h3>Disclosure of Interest</h3> None declared
AB0069 Strong age-dependent effects of dopamine on joint invasion in arthritis
Authors: L Van Nie, S Rehart, E Neumann, U Müller-Ladner, S Capellino
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Preventing synovial fibroblasts (SF) from migrating into the adjacent cartilage is a desirable therapeutic target in rheumatoid arthritis (RA) in order to avoid joint destruction and disability. In our previous studies we could show that RASF as well as SF from osteoarthritis (OA) patients express all dopamine receptor (DR) subtypes and dopamine stimulation alters pro-inflammatory cytokines (<i>Capellino S et al, A&amp;R 2014</i>). <h3>Objectives</h3> Therefore, we aimed to elucidate a potential dopamine-mediated impact on joint invasion and destruction in arthritis. <h3>Methods</h3> SF from RA and OA patients were obtained from patients undergoing knee joint replacement surgery (mean age: 74.3±11.3yrs at OA and 73.7±10.3 yrs at RA patients) to investigate dopamine receptor (DR)-distribution within the RA synovium and in the invasion zone, immunohistochemistry was performed for all five DR-subtypes. Migration and motility assays were performed under D1-like (D1DR and D5DR) and D2-like (D2DR, D3DR and D4DR) receptor stimulation. Dopamine effects on MMP3 and proMMP1 were evaluated using ELISA. <h3>Results</h3> D1DR, D4DR and D5DR were found to be stronger expressed close to the invasion zone and more cells were expressing the respective DR. Migration of RASF and OASF was significantly correlated with patients9 age at surgery: younger patients (≤75years) showed an increase in migration up to 78% whereas older patients (≥75years) showed a reduced migration of up to 50% (OA n=8; RA n=7). There was no difference between RA and OA patients and between D1-like and D2-like receptor stimulation. The same effect could be observed in the motility assay (OA n=5; RA n=6). MMP3 levels are altered under DR activation (OA n=6; RA n=6). <h3>Conclusions</h3> The high DR expression close to the invasion zone suggests a direct role of dopamine on RASF aggressiveness and may contribute to cartilage invasion. This was confirmed in the in vitro assays, and supports the idea of a therapeutic potential of the dopamine pathway in RA. <h3>Disclosure of Interest</h3> None declared
Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
Authors: J-H Liang, L Wang, R Peter Gale, W Wu, Y Xia, L Fan, J-Y Li, W Xu
Journal: Blood Cancer Journal (2017)

Extra-nodal natural-killer (NK)/T-cell lymphoma (ENKTL) is an aggressive disease common in Asia but rare in the West.2][3] These persons often respond to radiation therapy with or without anti-cancer drugs but relapse is common. 4,5Anthracycline-based regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) are often used to treat advanced-stage disease but are ineffective with overall survival (OS) less than a year. 37][8] The SMILE regimen (L-asparaginase, etoposide, methotrexate, ifosfamide and dexamethasone) regimen is reportedly effective in newly diagnosed persons with advanced-stage disease. 7,8A regimen of modified SMILE was also reported to be effective by Yang et al. 6 We tested a regimen of PEMD (pegaspargase, etoposide, methotrexate and dexamethasone) in 32 newly diagnosed advanced-stage subjects with ENKTL.Thirty-two consecutive subjects with newly diagnosed advanced-stage (stages III-IV) ENKTL were prospectively studied from July 2010 to December 2015.The study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.Subjects (32 patients) gave written informed consent in accordance with the Declaration of Helsinki.Biopsies were reviewed by ⩾ 2 experienced pathologists and diagnosis was based on WHO criteria. 1Baseline clinical variables including age, sex, Ann Arbor stage, serum lactate dehydrogenase, blood Epstein-Barr virus (EBV)-DNA levels (EBV-DNA copy number in whole blood was quantified by a real-time PCR based on the amplification of EBNA1 gene with the cut-off value of 5000 copies/ ml), B-symptoms, extra-nodal sites of disease, Eastern Cooperative Oncology Group (ECOG) performance score, bone marrow involvement, distant lymph-node involvement, International Prognostic Index (IPI) scores and prognostic index of natural killer lymphoma (PINK). 9pegaspargase, etoposide, methotrexate and dexamethasone was given as follows: methotrexate, 3.0 g/m 2 i.v. over 6 h on day 1; etoposide, 100 mg/m 2 i.v. on days 2-4; dexamethasone, 40 mg i.v. on days 1-4; pegaspargase, 2500 U/m 2 i.m. on day 2. Subjects received 4-6 cycles of PEMD every 3 weeks.Patients could receive autologous or allogeneic hematopoietic stem cell transplantation after achieving complete remission or partial remission.The decision was made according to the discretion of the treating physician, mainly on the basis of the patient's age, comorbidities, economy and wishes.Response criteria are reported using standard criteria. 10Subjects were evaluated after three cycles of PEMD, after completing PEMD and every 3 months for 2 years thereafter.Responses were classified as complete response (CR), unconfirmed CR (CRu), partial
THU0445 Gouty arthritis: decision making following dual energy ct scan in clinical practice, a retrospective analysis
Authors: M Gamala, S Linn-Rasker, M Nix, B Heggelman, J van Laar, P Pasker-de Jong, J Jacobs, R Klaasen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Gout is associated with joint damage, and increased cardiovascular morbidity; it is important to diagnose and treat it. However, although clinical presentation may be strongly suggestive of gout, joint aspiration and microscopy not always yield the diagnosis. The latest technique to visualize monosodium uric acid MSU depositions and thus to diagnose gout is Dual Energy CT scan (DECT).<sup>1</sup> <h3>Objectives</h3> To establish whether DECT is a diagnostic tool, i.e. associated with initiation or discontinuation of a urate lowering drug (ULD). Second, whether DECT results (gout deposition y/n) can be predicted by clinical and laboratory variables. <h3>Methods</h3> Digital medical records of 147 consecutive patients with clinical suspicion of gout at the outpatient clinic of the Department of Rheumatology of Meander Medical Centre, Amersfoort, the Netherlands who underwent DECT between January 1, 2013 and December 31, 2014 were analyzed retrospectively. Collected were clinical data including medication before and after DECT, lab results, and results from diagnostic joint aspiration and DECT. The relationship between DECT results and clinica, and laboratory results was evaluated by univariate regression analyses; predictors showing a p&lt;0.10 were entered in a multivariate logistic regression model with the DECT result as outcome variable. A manual backward stepwise technique was applied. <h3>Results</h3> 87 patients were diagnosed with gout based on demonstration of MSU crystals in synovial fluid (SF) or positive DECT result. In 30 patients, DECT was the only conformation of gout; in 29 of them ULD was started and in 1 it was intensified. Following DECT, the current ULD was stopped in 3 patients. The clinical and laboratory variables associated with the DECT result are presented in table 1. In the multivariable regression model, cardiovascular disease y/n (OR 3.07, 95% CI 1.26–7.47), disease duration in years (OR 1.008, 95% CI 1.001–1.016), frequency of attack per year (OR 1.23, 95% CI 1.07–1.42), creatinine clearance in ml/min (OR 2.03, 95% CI 0.91–1.00) were independently associated with positive DECT results. <h3>Conclusions</h3> DECT has impact on clinical decisions on ULD therapy. It may be a useful diagnostic imaging tool for patients who cannot undergo joint aspiration because of contraindications or with difficult to aspirate joints, or those who refuse joint aspiration. <h3>References</h3> Choi HK et al. Dual energy CT in gout: a prospectieve validation study. Ann Rheum Dis 2012; 71:1466–71. <h3>Disclosure of Interest</h3> None declared
What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?
Authors: Marc Ruel, Subodh Verma, Deepak L. Bhatt
Journal: JAMA Cardiology (2017)

This Viewpoint discusses various randomized clinical trials evaluating optimal treatment options, including coronary artery bypass grafting and percutaneous coronary intervention, for patients with left main coronary stenosis.
AB0855 The disparities between fracture risk assessment (FRAX) with bmd and without BMD in korean patients with ankylosing spondylitis- multicenter trial
Authors: S-R Kwon, ST Choi, C-H Suh, H-A Kim, J-Y Jung, S-S Kim, S-H Kim, J-M Kim, S-Y Lee
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> The aims of this study are to determine the proportion of patients with ankylosing spondylitis (AS) at high risk for major osteoporotic and hip fractures of Fracture risk assessment (FRAX) in Korean and to determine if a care gap exists for high risk. <h3>Methods</h3> This study is a multicenter study including 163 AS patients in 5. All of the AS patients fulfilled the modified New York criteria. The classification of osteoporosis according to WHO criteria was based on T-score ≤ -2.5. The FRAX criteria for high risk of osteoporotic fracture, which is 10-year probability of ≥20% for major osteoporotic fracture or ≥3% for hip fracture, were calculated by the FRAX tool including the bone mineral density (BMD) values. We assessed various demographic factors, clinical and laboratory findings of AS, and medication use for AS and osteoporosis, and then evaluated the risk factors for osteoporotic fracture. <h3>Results</h3> The mean age of AS patients was 44.3 years, and 42 patients were female (25.2%) with 23 postmenopausal women 56.1%. Osteoporotic fracture was detected in 16 (9.8%) patients with AS. Among the 16 patients ≥65 years of age, 2 (12.5%) and 8 (50%) were at high risk for a major osteoporotic fracture (10-year probability &gt;20%) and hip fracture (&gt;3%), respectively. Among patients with BMD measurements (n=106), the 10-year risk of a major osteoporotic fracture and hip fracture calculated with BMD was significantly higher than in those without BMD measurements (P=0.001, P=0.002) respectively. The 10-year risk of a major osteoporotic and hip fracture fracture calculated with BMD was significantly higher than in those without BMD measurements (P&lt;0.001, P=0.003) respectively among male patients with BMD measurements (n=74). There is no statistic difference of the 10-year risk of a major osteoporotic fracture and hip fracture between those calculated with BMD and those without BMD measurements (P&gt;0.05) respectively among female patients (n=32). <h3>Conclusions</h3> A substantial gap exists between FRAX with BMD and without BMD in Korean patients with AS. <h3>Disclosure of Interest</h3> None declared